Q BIOMED INC. TO PRESENT AT BIOTECH SHOWCASE(™) 2016

NEW YORK, January 5, 2106 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company announced today that Denis Corin, Chief Executive Officer, will present at the Biotech Showcase(™) 2016 Conference to be held January 11 through January 13, 2016 in San Francisco, California.   Details of QBioMed’s’ participation are as follows: Event:   Biotech […]

Read More

Q BIOMED INC. APPOINTS INDUSTRY EXECUTIVE TO MANAGEMENT TEAM

Company welcomes David Laskow-Pooley, former GSK, Abbott, Amersham executive to its management team   NEW YORK, December 16, 2015 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to welcome David Laskow-Pooley to the Q Team as VP Scientific & Product Development. Mr. Laskow-Pooley has 30 years of experience in all aspects […]

Read More

Q BIOMED INC. UPLISTED TO OTCQB MARKET

NEW YORK, November 13, 2015 — Q BioMed Inc. (OTCQB: QBIO), today announced that its common stock is being uplisted to the OTCQB effective November 13, 2015.   The OTCQB® Venture Marketplace is for entrepreneurial and development stage U.S. and international companies. To be eligible, companies must be current in their reporting and undergo an […]

Read More

Q BIOMED INC. STRENGTHENS ADVISORY BOARD

Company welcomes Dr. Susan E Quaggin, Dr. George Nikopoulos and Dr. MaryJane Rafii to its list of strategic advisors   NEW YORK, November 12, 2015 — Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company is pleased to announce the addition of Mannin Research Inc. executives, Dr. Susan E Quaggin and Dr. George Nikopoulos […]

Read More

Vision Monday – Q BioMed Inc. and Mannin Research Inc. Sign Definitive License Agreement

Latest News Q BioMed Inc. and Mannin Research Inc. Sign Definitive License Agreement  By Staff Friday, November 6, 2015 12:18 AM NEW YORK—Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company has signed a definitive license, with the option to acquire, the platform technology assets of Mannin Research Inc., a biotechnology company leading the […]

Read More

GEN News – Q BioMed Licenses Mannin Platform for Vascular Drugs

GEN News Highlights Oct 30, 2015 Q BioMed Licenses Mannin Platform for Vascular Drugs Q BioMed said today it agreed to exclusively license—with an option to acquire—platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics. Mannin’s primary focus is developing a first-in-class therapeutic eye-drop for glaucoma in adults and […]

Read More

Q BioMed Inc. and Mannin Research Inc Sign Definitive License Agreement

Platform technology well positioned to be a First-In-Class molecule for the treatment of glaucoma as well as cystic kidney disease and others. NEW YORK, October 30, 2015 Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company is pleased to announce it has signed a definitive license, with the option to acquire, the platform technology assets […]

Read More

Q BioMed Inc. Enters into Partnership with the Strategic and Scientific Advisory Firm Wombat Capital, Ltd.

Companies to collaborate on innovative Life Sciences asset discovery, evaluation and acquisition.   NEW YORK, October 13, 2015 — Q BioMed Inc (OTC: QBIO), a biotechnology acceleration and development company, has entered into a strategic relationship with Wombat Capital, Ltd., a New York and Paris, France based strategic and scientific advisory firm.. This collaborative arrangement […]

Read More

Q BioMed Inc. is pleased to announce a Letter-Of-Intent to exclusively in-license and ultimately acquire the assets of Mannin Research Inc.

Technology asset well positioned to be a First-In-Class molecule for the treatment of Glaucoma, a leading cause of blindness in the US and around the world. NEW YORK, September 21, 2015 — Q BioMed Inc (OTC: QBIO), a biotechnology acceleration and development company is pleased to announce a Letter of Intent to in-license and ultimately […]

Read More
Social media & sharing icons powered by UltimatelySocial